Research Article
Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis
Figure 3
Comparative survival outcomes according to grouping composite disease stage and pretreatment SIRI groups (red line: Group 1, IIIB and SIRI < 1.9; dark blue line: Group 2, IIIB and SIRI ≥ 1.9; green line: Group 3, IIIC and SIRI < 1.9; and orange line: Group 4, IIIC and SIRI ≥ 1.9): (a) progression-free survival; (b) overall survival.
(a) |
(b) |